Gene Symbol: DPM1
Full Name: Dolichol-Phosphate Mannosyltransferase Subunit 1
Chromosomal Location: 20q13.13
NCBI Gene ID: 8813
OMIM: 603503
Ensembl ID: ENSG00000024219
UniProt: O60711
The DPM1 gene encodes the catalytic subunit of the dolichol-phosphate mannose (DPM) synthase complex . DPM1 is the enzymatically active component of the complex, which also includes DPM2 (regulatory subunit) and DPM3 (scaffold subunit). This complex catalyzes the synthesis of dolichol-phosphate mannose (DPM), a critical donor substrate for protein glycosylation in the endoplasmic reticulum .
DPM1 possesses the enzymatic activity responsible for:
- Mannose Transfer: Catalyzes the transfer of mannose from GDP-mannose to dolichol-phosphate
- DPM Synthesis: Produces dolichol-phosphate mannose as the key intermediate
- Glycosylation Initiation: DPM is the essential donor for N-linked protein glycosylation
The DPM complex is essential for:
- Protein N-glycosylation: Over 50% of human proteins are glycosylated
- ER Quality Control: Glycosylation is crucial for proper protein folding
- Membrane Protein Maturation: Many neuronal receptors require proper glycosylation
DPM1 dysfunction may contribute to Alzheimer's disease through multiple mechanisms:
- Amyloid Processing: Proper glycosylation affects amyloid precursor protein (APP) processing and amyloid-beta generation
- Tau Glycosylation: Abnormal glycosylation patterns have been documented in tauopathies
- Synaptic Dysfunction: Glycosylation of synaptic receptors and adhesion molecules is essential for synaptic plasticity
- ER Stress: Impaired glycosylation triggers unfolded protein response (UPR)
- Alpha-Synuclein: Glycosylation patterns influence alpha-synuclein aggregation and toxicity
- Protein Homeostasis: Disrupted glycosylation affects cellular protein quality control
- Dopaminergic Vulnerability: Glycosylation defects may contribute to neuronal susceptibility
DPM1 mutations cause Congenital Disorder of Glycosylation Type I (CDG), characterized by:
- Severe Neurological Impairment: Developmental delay, intellectual disability
- Ataxia: Cerebellar involvement causing coordination problems
- Seizures: Epileptic activity in affected individuals
- Systemic Features: Coagulopathy, dysmorphic features, immune dysfunction
DPM1 is ubiquitously expressed with high levels in:
- Brain: Neurons throughout the cerebral cortex, hippocampus, and cerebellum
- Liver: Hepatocytes with extensive ER content
- Muscle: Skeletal and cardiac muscle
- Pancreas: Islet cells
DPM1 is a potential therapeutic target:
- CDG Treatment: Enzyme replacement or substrate supplementation approaches
- ER Stress Modulators: Reducing UPR burden in glycosylation defects
- Chaperone Therapy: Small molecules to enhance DPM complex function
- DPM1 mutations cause autosomal recessive CDG-Ia (the most common CDG type)
- Compound heterozygous mutations often cause milder phenotypes
- Carrier testing is available for at-risk families
DPM1 dysfunction is clinically relevant for:
- Diagnosis: Genetic testing for DPM1 mutations
- Newborn Screening: Metabolic screening can detect some CDG types
- Prognosis: Phenotype varies from mild to severe based on mutation type